-
Mashup Score: 5Oncology Community Mourns the Loss of Dr Jeffrey S. Weber, 2016 Giant of Cancer Care® Winner - 3 month(s) ago
Jeffrey S. Weber, MD, PhD, inductee of the 2016 Giants of Cancer Care award in Melanoma, has died.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 5Oncology Community Mourns the Loss of Dr Jeffrey S. Weber, 2016 Giant of Cancer Care® Winner - 3 month(s) ago
Jeffrey S. Weber, MD, PhD, inductee of the 2016 Giants of Cancer Care award in Melanoma, has died.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Oncology Community Mourns the Loss of Dr Jeffrey S. Weber, 2016 Giant of Cancer Care® Winner in Melanoma #melsm #oncology https://t.co/c7tkzDHcb5
-
-
Mashup Score: 5
Adjuvant pembrolizumab did not have a significant impact on long-term HRQOL outcomes in patients with resected stage III melanoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Adjuvant Pembrolizumab Does Not Affect Long-Term HRQOL in Stage III Melanoma @EORTC @TheLancetOncol #melsm #oncology https://t.co/XZN9YTZjAj
-
-
Mashup Score: 5Oncology Community Mourns the Loss of Dr Jeffrey S. Weber, 2016 Giant of Cancer Care® Winner - 3 month(s) ago
Jeffrey S. Weber, MD, PhD, inductee of the 2016 Giants of Cancer Care award in Melanoma, has died.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Oncology Community Mourns the Loss of Dr Jeffrey S. Weber, 2016 Giant of Cancer Care® Winner in Melanoma #melsm #oncology https://t.co/c7tkzDHcb5
-
-
Mashup Score: 0
The addition of BNT111 to cemiplimab has produced clinical activity in anti-PD-(L)1 relapsed/refractory unresectable stage III or IV melanoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
BNT111 Plus Cemiplimab Generates Responses in Unresectable stage III/IV Melanoma #melsm #oncology https://t.co/C7WnbZ6NzF
-
-
Mashup Score: 4New Data With RP1 Plus Nivolumab in PD-1–Refractory Melanoma Build on Positive Findings - 5 month(s) ago
The combination of RP1 and nivolumab was safe and effective in patients with anti–PD-1-failed advanced melanoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
New Data With RP1 Plus Nivolumab in PD-1–Refractory Melanoma Build on Positive Findings #melsm #oncology https://t.co/cy6uzaRnDA
-
-
Mashup Score: 4New Data With RP1 Plus Nivolumab in PD-1–Refractory Melanoma Build on Positive Findings - 5 month(s) ago
The combination of RP1 and nivolumab was safe and effective in patients with anti–PD-1-failed advanced melanoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
New Data With RP1 Plus Nivolumab in PD-1–Refractory Melanoma Build on Positive Findings #melsm #oncology https://t.co/cy6uzaRnDA
-
-
Mashup Score: 4New Data With RP1 Plus Nivolumab in PD-1–Refractory Melanoma Build on Positive Findings - 6 month(s) ago
The combination of RP1 and nivolumab was safe and effective in patients with anti–PD-1-failed advanced melanoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
New Data With RP1 Plus Nivolumab in PD-1–Refractory Melanoma Build on Positive Findings #melsm #oncology https://t.co/cy6uzaRnDA
-
-
Mashup Score: 1
Patrick Ott, MD, PhD, discusses the investigation of cancer vaccines, highlighting the clinical implications of this treatment modality in melanoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
The personalized cancer vaccine research paradigm is expanding, with particular advancements occurring in patients with high-risk melanoma, in whom vaccines have been shown to induce and strengthen responses to immunotherapy. @DanaFarber #melsm #oncology https://t.co/PxB6LHiI9T https://t.co/q1aimwllEg
-
-
Mashup Score: 2Merck Discontinues KeyVibe-010 Trial of Vibostolimab/Pembrolizumab in Resected High-Risk Melanoma - 6 month(s) ago
The phase 3 KeyVibe-010 trial of adjuvant vibostolimab plus pembrolizumab in patients with resected high-risk melanoma has been discontinued.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Merck Discontinues KeyVibe-010 Trial of Vibostolimab/Pembrolizumab in Resected High-Risk Melanoma #melsm #oncology https://t.co/REbphztVpB
-
Oncology Community Mourns the Loss of Dr Jeffrey S. Weber, 2016 Giant of Cancer Care® Winner in Melanoma #melsm #oncology https://t.co/c7tkzDHcb5